CSL · 1 month ago
Associate Director, Data Science & AI
CSL Behring is a global biotherapeutics leader focused on saving lives through innovative therapies. The Associate Director of Commercial Data Science & AI will lead the strategy and application of advanced analytics, machine learning, and AI solutions to enhance commercial outcomes and drive innovation within the company.
BiotechnologyHealth CareHealth DiagnosticsMedical
Responsibilities
Lead development and deployment of advanced analytics and AI models to address critical commercial challenges (patient identification in rare disease, HCP segmentation, Medical and Tender use cases)
In close partnership with ABCIA Commercial, Medical Affairs, and Market Access teams to ensure solutions are aligned with strategic business needs
Translate business problems into well-defined data science use cases and develop proof-of-concept pilots through to production
Drive adoption of AI-enabled tools across the commercial organization, ensuring business users understand and trust the outputs
Partner with I&T and Data Governance to ensure responsible AI practices, data quality, and scalable infrastructure
Drive CSL innovation in the field, leading to high visibility publications in top AI conferences and patents around Generative AI, reasoning, multi-agent systems, etc
Establish KPIs and frameworks to measure ROI and business impact of data science projects
Qualification
Required
Bachelor's degree required. In Data Science, AI, Computer Science, Statistics, Applied Mathematics, or related quantitative discipline preferred
10+ years of experience in advanced analytics, data science, or (Gen)AI within pharma/biotech or healthcare; commercial analytics experience strongly preferred
Strong track record of developing and deploying machine learning models in commercial or clinical contexts
Strong analytical and problem-solving skills, with the ability to interpret complex data and make informed decisions
A deep understanding of the pharmaceutical industry, including regulatory requirements, market dynamics, and emerging AI technologies, with the foresight to identify and map both current and future AI opportunities
Experience leading cross-functional AI/ML initiatives from concept through deployment
Familiarity with cloud environments (AWS and Snowflake), data engineering workflows, and modern ML frameworks (TensorFlow, PyTorch, scikit-learn) and familiarity with no-code data science SaaS tools
Demonstrated ability to translate business problems into analytical solutions and communicate results to senior leadership
Ability to adapt strategies and approaches in a rapidly evolving technological landscape
Preferred
Experience in rare disease patient-finding models a plus
Experience building evaluation frameworks for LLMs (factuality, faithfulness, bias, toxicity) and human-in-the-loop review
Knowledge of responsible AI frameworks, data governance, and compliance in pharma settings
Experience leading design, training/fine-tuning, and evaluation of ML/LLM/Agentic systems (retrieval-augmented generation, tool-use, routing, multi-agent workflows)
Ability to thrive in a matrix environment and influence without direct authority
Benefits
CSL employees that work at least 30 hours per week are eligible for benefits effective day 1.
CSL offers resources and benefits, from health care to financial protection, so you can focus on doing work that matters.
Our benefits are designed to support the needs of our employees at every stage of their life.
Whether you are considering starting a family, need help paying for emergency back up care or summer camp, looking for mental health resources, planning for your financial future, or supporting your favorite charity with a matching contribution, CSL has many benefits to help achieve your goals.
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase